[ad_1]
A study showed that Remdesivir, an experimental drug that scientists hope to use to treat the Corona virus, improves coronavirus symptoms and reduces lung damage in a preliminary study in monkeys.
According to the report of the American magazine “newsweek”, the scientists infected two groups of 6 rhesus macaques in the corona virus, and 12 hours after the animals were infected, the team gave them the medicine once a day for 6 days, and the team said the dose schedule simulates what is administered to COVID-Human 19 patients in clinical studies.
Resverf’s success in monkeys
The team also regularly investigated the monkeys’ symptoms and the amount of virus they carried, and after 7 days, they killed the animals and performed an autopsy.
“Early 12 hours after the first treatment,” the team said, the virus levels decreased in the animals’ lower respiratory tract.
However, virus levels were not reduced in the nose, throat, or rectal swabs taken from drug-treated animals after 12 hours, but after 4 days, virus levels were lower in throat swabs.
The studies revealed that the autopsy showed that the viral load in the lungs of the animals that received the drug “was significantly less and there was a clear decrease in damage to the lung tissue.”
The team concluded that “treatment starting early during infection has clear clinical benefit in SARS-coV-2 macaques, and these data support the initiation of early design therapy in patients with COVID-19 to prevent progression to acute pneumonia “
But the researchers admitted: “Due to the acute nature of the disease in macaques, it is difficult to translate the timing of treatment used for the corresponding stages of the disease in humans.”
Scientists said the drug Remicidiver was given “near the peak of virus multiplication in the lungs as indicated by viral loads” and tests of the lower respiratory tract, and “the first effects of the treatment on clinical signs and virus replication in 12 hours. “
These types of antiviral drugs generally become less effective against ARV infections when treatment is delayed, according to the team. “Therefore, REMSIVER treatment in patients with COVID-19 should begin as soon as possible to achieve the maximum therapeutic effect.”
